Tumour markers of prognosis in colorectal cancer

Abstract

16 November 2011 This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

Shown for reading. Its publisher allows quoting it, not republishing it.

References 97

1. 1.

   ASTLER V. B., COLLER F. A. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg. 1954;139(6):846-852.

   Not in our library10.1097/00000658-195406000-00015

2. 2.

   Amaya H., Tanigawa N., Lu C., Matsumura M., Shimomatsuya T., Horiuchi T., Muraoka R. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett. 1997;119(2):227-235.

   Not in our library10.1016/s0304-3835(97)00280-2

3. 3.

   Ambiru S., Miyazaki M., Ito H., Nakagawa K., Shimizu H., Nukui Y., Nozawa S., Okuno A., Yoshitomi H., Nakajima N. A prospective study of prognostic value of type IV collagenase activity in colorectal cancer tissue. Dig Dis Sci. 1997;42(8):1660-1665.

   Not in our library10.1023/a:1018801229372

4. 4.

   Andersen S. N., Løvig T., Breivik J., Lund E., Gaudernack G., Meling G. I., Rognum T. O. K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol. 1997;32(1):62-69.

   Not in our library10.3109/00365529709025065

5. 5.

   Apolinario R. M., van der Valk P., de Jong J. S., Deville W., van Ark-Otte J., Dingemans A. M., van Mourik J. C., Postmus P. E., Pinedo H. M., Giaccone G. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol. 1997;15(6):2456-2466.

   Not in our library10.1200/jco.1997.15.6.2456

6. 6.

   Arribas R., Capellà G., Tórtola S., Masramon L., Grizzle W. E., Perucho M., Peinado M. A. Assessment of genomic damage in colorectal cancer by DNA fingerprinting: prognostic applications. J Clin Oncol. 1997;15(10):3230-3240.

   Not in our library10.1200/jco.1997.15.10.3230

7. 7.

   Augenlicht L. H., Wadler S., Corner G., Richards C., Ryan L., Multani A. S., Pathak S., Benson A., Haller D., Heerdt B. G. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res. 1997;57(9):1769-1775.

   Not in our library

8. 8.

   Baas I. O., Mulder J. W., Offerhaus G. J., Vogelstein B., Hamilton S. R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 1994;172(1):5-12.

   Not in our library10.1002/path.1711720104

9. 9.

   Baretton G. B., Diebold J., Christoforis G., Vogt M., Müller C., Dopfer K., Schneiderbanger K., Schmidt M., Löhrs U. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer. 1996;77(2):255-264.

   Not in our library10.1002/(sici)1097-0142(19960115)77:2<255::aid-cncr6>3.0.co;2-l

10. 10.

    Baretton G. B., Vogt M., Müller C., Diebold J., Schneiderbanger K., Schmidt M., Löhrs U. Prognostic significance of p53 expression, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (stages IB and II). Scand J Gastroenterol. 1996;31(5):481-489.

    Not in our library10.3109/00365529609006769

11. 11.

    Bell S. M., Scott N., Cross D., Sagar P., Lewis F. A., Blair G. E., Taylor G. R., Dixon M. F., Quirke P. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993;104(1):57-64.

    Not in our library10.1016/0016-5085(93)90835-z

12. 12.

    Belluco C., Guillem J. G., Kemeny N., Huang Y., Klimstra D., Berger M. F., Cohen A. M. p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol. 1996;14(10):2696-2701.

    Not in our library10.1200/jco.1996.14.10.2696

13. 13.

    Benhattar J., Losi L., Chaubert P., Givel J. C., Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology. 1993;104(4):1044-1048.

    Not in our library10.1016/0016-5085(93)90272-e

14. 14.

    Bennett M. A., Kay E. W., Mulcahy H., O'flaherty L., O'donoghue D. P., Leader M., Croke D. T. ras and p53 in the prediction of survival in Dukes' stage B colorectal carcinoma. Clin Mol Pathol. 1995;48(6):M310-M315.

    Not in our library10.1136/mp.48.6.m310

15. 15.

    Bhatavdekar J. M., Patel D. D., Ghosh N., Chikhlikar P. R., Trivedi T. I., Suthar T. P., Doctor S. S., Shah N. G., Balar D. B. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum. 1997;40(7):785-790.

    Not in our library10.1007/bf02055433

16. 16.

    Bosari S., Moneghini L., Graziani D., Lee A. K., Murray J. J., Coggi G., Viale G. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol. 1995;26(5):534-540.

    Not in our library10.1016/0046-8177(95)90250-3

17. 17.

    Bosari S., Viale G., Bossi P., Maggioni M., Coggi G., Murray J. J., Lee A. K. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst. 1994;86(9):681-687.

    Not in our library10.1093/jnci/86.9.681

18. 18.

    Bosari S., Viale G. The clinical significance of p53 aberrations in human tumours. Virchows Arch. 1995;427(3):229-241.

    Not in our library10.1007/bf00203389

19. 19.

    Brett M. C., Pickard M., Green B., Howel-Evans A., Smith D., Kinsella A., Poston G. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol. 1996;22(2):182-185.

    Not in our library10.1016/s0748-7983(96)90827-6

20. 20.

    Chambers A. F., Matrisian L. M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89(17):1260-1270.

    Not in our library10.1093/jnci/89.17.1260

21. 21.

    Cohen A. M., Tremiterra S., Candela F., Thaler H. T., Sigurdson E. R. Prognosis of node-positive colon cancer. Cancer. 1991;67(7):1859-1861.

    Not in our library10.1002/1097-0142(19910401)67:7<1859::aid-cncr2820670707>3.0.co;2-a

22. 22.

    Costa A., Doci R., Mochen C., Bignami P., Faranda A., Gennari L., Silvestrini R. Cell proliferation-related markers in colorectal liver metastases: correlation with patient prognosis. J Clin Oncol. 1997;15(5):2008-2014.

    Not in our library10.1200/jco.1997.15.5.2008

23. 23.

    Cox L. S., Lane D. P. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays. 1995;17(6):501-508.

    Not in our library10.1002/bies.950170606

24. 24.

    Dix B. R., Robbins P., Soong R., Jenner D., House A. K., Iacopetta B. J. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer. 1994;59(6):747-751.

    Not in our library10.1002/ijc.2910590606

25. 25.

    Dorudi S., Hanby A. M., Poulsom R., Northover J., Hart I. R. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer. 1995;71(3):614-616.

    Not in our library10.1038/bjc.1995.119

26. 26.

    Elnatan J., Goh H. S., Smith D. R. C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer. 1996;32A(3):491-497.

    Not in our library10.1016/0959-8049(95)00567-6

27. 27.

    Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.

    Not in our library10.1016/0092-8674(90)90186-i

28. 28.

    Findlay M. P., Cunningham D., Morgan G., Clinton S., Hardcastle A., Aherne G. W. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer. 1997;75(6):903-909.

    Not in our library10.1038/bjc.1997.159

29. 29.

    Ganesh S., Sier C. F., Heerding M. M., van Krieken J. H., Griffioen G., Welvaart K., van de Velde C. J., Verheijen J. H., Lamers C. B., Verspaget H. W. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer. 1997;75(12):1793-1801.

    Not in our library10.1038/bjc.1997.306

30. 30.

    Goh H. S., Yao J., Smith D. R. p53 point mutation and survival in colorectal cancer patients. Cancer Res. 1995;55(22):5217-5221.

    Not in our library

31. 31.

    Griffiths L., Stratford I. J. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer. 1997;76(6):689-693.

    Not in our library10.1038/bjc.1997.447

32. 32.

    Hermanek P., Wiebelt H., Staimmer D., Riedl S. Prognostic factors of rectum carcinoma--experience of the German Multicentre Study SGCRC. German Study Group Colo-Rectal Carcinoma. Tumori. 1995;81(3 Suppl):60-64.

    Not in our library

33. 33.

    Hoffmann D., Moore J., Roder D. Trends in survival from colonic cancer: the impact of subspecialization. Aust N Z J Surg. 1997;67(12):842-845.

    Not in our library10.1111/j.1445-2197.1997.tb07608.x

34. 34.

    Jackman A. L., Kelland L. R., Kimbell R., Brown M., Gibson W., Aherne G. W., Hardcastle A., Boyle F. T. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer. 1995;71(5):914-924.

    Not in our library10.1038/bjc.1995.178

35. 35.

    Jen J., Kim H., Piantadosi S., Liu Z. F., Levitt R. C., Sistonen P., Kinzler K. W., Vogelstein B., Hamilton S. R. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994;331(4):213-221.

    Not in our library10.1056/nejm199407283310401

36. 36.

    Johnston P. G., Drake J. C., Trepel J., Allegra C. J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. 1992;52(16):4306-4312.

    Not in our library

37. 37.

    Johnston P. G., Fisher E. R., Rockette H. E., Fisher B., Wolmark N., Drake J. C., Chabner B. A., Allegra C. J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol. 1994;12(12):2640-2647.

    Not in our library10.1200/jco.1994.12.12.2640

38. 38.

    Johnston P. G., Lenz H. J., Leichman C. G., Danenberg K. D., Allegra C. J., Danenberg P. V., Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995;55(7):1407-1412.

    Not in our library

39. 39.

    Kapitanović S., Radosević S., Kapitanović M., Andelinović S., Ferencić Z., Tavassoli M., Primorać D., Sonicki Z., Spaventi S., Pavelic K. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997;112(4):1103-1113.

    Not in our library10.1016/s0016-5085(97)70120-3

40. 40.

    Kay E. W., Mulcahy H., Walsh C. B., Leader M., O'Donoghue D. Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology. 1994;25(5):455-461.

    Not in our library10.1111/j.1365-2559.1994.tb00007.x

Cited by papers we hold 1

• MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance · 2016
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.